I agree Goosebumps. Leronlimab has vast potential. It might seem that a large pharmaceutical company could develop this faster than little CYDY. But large doesn't mean fast. If they have an existing inferior drug for an indication, they may hold off developing Leron until they can milk the profits pushing a second rate drug. Leronlimab will save lives, many lives. I've held this stock for over three years. It may seem counter intuitive, but I believe the greatest positive impact will come from being developed by an independent, lean company that is eager to grow.